Browsing Category
Drug research
Syntara’s $10M Raise: Fueling Drug Development
Syntara's $10M capital raise is propelling its drug development strategy into a new era.
In this exclusive interview, CEO Gary Phillips unveils the transformative steps taken by Syntara Ltd, from its rebranding efforts to the strategic…
AstraZeneca acquires US vaccine company for $1.1bn
AstraZeneca has acquired its first vaccine company for $1.1bn. This will allow the company to expand its vaccine and immunotherapy business, which it established during the Covid pandemic.
The largest drugmaker in Britain has agreed to…
Weight loss drug manufacturer plots a ‘buy Now, Pay Later’ offer
Novo Nordisk wants to help more people get Wegovy jabs, including those who are currently unable to access them.
Novo Nordisk, a maker of obesity drugs, said that it would offer countries the option to "buy now and pay later" for its…
AstraZeneca defends its Covid-19 injection against accusations that it was defective
AstraZeneca has contested accusations that the Covid-19 vaccine was "defective", after a vaccine patient sued for damages, claiming to have suffered a severe side-effect.
The Anglo-Swedish pharmaceutical company, which developed the…
AstraZeneca signs a deal for an oral obesity drug that boosts profit forecasts
AstraZeneca will enter the race to develop a weight-loss pill. It is working on a new class of drugs, which it hopes to use in developing nations to combat obesity.
The Anglo-Swedish pharmaceutical company announced on Thursday a…
Early drug treatment for Alzheimer’s disease is beneficial according to new studies
Researchers from Eisai and Eli Lilly presented a study that showed the benefits for patients of using new Alzheimer's medications very early in its development.
The Japanese pharmaceutical group Eisai has revealed that a new analysis…
AstraZeneca praises “clinically meaningful” cancer drug trial results
AstraZeneca announced the full results of its trials at a medical conference on Monday, in an attempt to reassure investors about their plans to replace chemotherapy with a targeted drug.
David Fredrickson said that it was "a massive…
Merck opens a £1bn London research center with a plea for government support to industry
Merck's chief research officer has called for the UK government make the country more welcoming of pharma companies. This is ahead of next week, when the US-based company will break ground in London on a £1bn Research Centre.
Dean Li,…
GSK signs £2.5bn deal with China Zhifei for shingles vaccine
GSK signed a contract with Zhifei - China's biggest vaccine company by revenue - to double the global sales of GSK's shingles vaccine before 2026.
The UK-based company reported that Zhifei has agreed to purchase Shingrix from GSK, the…
Moderna reports success in trials for the dual Covid and influenza vaccine
Moderna's Covid-19 combined with influenza vaccine performed as well as separate shots during an early-stage trial. This gives the US biotech firm hope that the more convenient method of protection against diseases could be approved before…
Research links Covid antiviral to mutations that are ‘transmissible,’ according to the…
The blockbuster drug Merck developed to treat Covid-19 was linked to mutations that are transmitted when coronaviruses spread between patients. This finding will increase scrutiny over its effectiveness and the billions of dollars spent by…
UK invests overseas to fight antimicrobial resistance
The UK has invested £210mn to track superbugs in Asia and Africa in order to combat antimicrobial resistance in Britain before these pathogens reach the country.
The funding announcement was made on Wednesday, as Health Secretary Steve…
Already, the Ozempic-killers are generating fat profits
A booming weight-loss drug market has investors scrambling for a piece of the action
After Copenhagen-headquartered Novo Nordisk published trial data this week suggesting its weight-loss jab Wegovy cut the risk of heart attacks…
How a Swedish startup reignited the hunt for an Alzheimer’s drug
Gunilla Osswald describes her final act at AstraZeneca in a quiet voice. After 28 years trying to develop treatments for brain disorders patients, she was given the "sad task" of closing a large Swedish Research and Development site in…